High Psoriasis Comorbidity Burden Identified in People of Color
Researchers called for dermatologists to recognize psoriasis-associated comorbidities, which can be managed more effectively with a multidisciplinary care team.
Apr 9, 2025
MEETING BRIEF
AAD 2025
The latest news from AAD 2025 focused on psoriasis including abstracts, features, and helpful conference information.
Addressing Sleep & Mental Health in Patients With Psoriasis
Addressing Sleep & Mental Health in Patients With Psoriasis
Collaborating with patients is essential for addressing sleep disturbances and mental health comorbidities, which are under-recognized in psoriasis.
Excellent Long-Term Data for TYK2 Inhibitor ESK-001 in Psoriasis
Excellent Long-Term Data for TYK2 Inhibitor ESK-001 in Psoriasis
ESK-001, a TYK2 inhibitor, showed promising efficacy and good tolerability in phase 2 for plaque psoriasis, prompting a phase 3 trial.
Cutaneous Immune-Related AEs May Predict Toxicities in Patients Treated With ICI
Cutaneous Immune-Related AEs May Predict Toxicities in Patients Treated With ICI
Patients with melanoma and cIRAEs on immune checkpoint inhibitors face higher toxicity risks but improved survival, warranting close monitoring.
Bempikibart Shows Potential for Hair Regrowth in Alopecia Areata
Bempikibart Shows Potential for Hair Regrowth in Alopecia Areata
Bempikibart demonstrated durable, clinically meaningful responses in patients with severe alopecia areata in the phase 2 SIGNAL-AA trial.
Advertisement
PW QUIZ
Advertisement
Baricitinib Regrows Hair in Adolescents With AA
Baricitinib Regrows Hair in Adolescents With AA
Baricitinib significantly improved scalp hair regrowth, with 80% or more scalp hair coverage in 42% of adolescents with severe alopecia areata (AA) at 36 weeks, with a favorable safety profile. Similarly, eyebrow and eyelash regrowth were also significantly improved.
A ‘TYK’ Above Placebo: ICP-488 in Plaque Psoriasis
A ‘TYK’ Above Placebo: ICP-488 in Plaque Psoriasis
Once-daily ICP-488, a selective oral tyrosine kinase 2 (TYK2) inhibitor, significantly improved PASI scores in patients with moderate-to-severe plaque psoriasis compared with placebo at week 12, with a safety profile similar to placebo.
Oral Psoriasis Drug Produces Significant Skin Clearance in Phase 3 Trial
Oral Psoriasis Drug Produces Significant Skin Clearance in Phase 3 Trial
New findings from the phase 3 ICONIC-LEAD trial suggest that once-daily oral icotrokinra demonstrated significant, durable skin clearance and a safety profile similar to placebo in patients with plaque psoriasis.
Upadacitinib Efficacy in Palmoplantar Pustulosis
Upadacitinib Efficacy in Palmoplantar Pustulosis
Upadacitinib efficacy and safety in treating palmoplantar pustulosis (PPP) revealed rapid and sustained pustule clearance with an acceptable safety profile. The researchers also introduced a novel mouse model to further advance PPP research by providing insights into disease mechanisms and potential treatment targets.
Stay connected to the latest news with Physician’s Weekly
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
